Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Cleveland Clinic's 20th Annual ASH Review
A

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Novel Agent to the Backbone? How Can Next Generation BTKis Distinguish Themselves from Ibrutinib?

By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
167 views
April 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Leukemia
15:23
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

Feat. J. Park
13:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

Feat. E. Stein
30:21
International CML Foundation

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

Feat. M. Mauro
04:55
ASH 2022 Conference Coverage

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

Feat. E. Stein
04:22
EHA 2022 Conference Coverage

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previousl…

Feat. E. Stein
54:58
PleXus Communications

Expert Perspectives on Treating High-Risk and R/R AML

Feat. E. Stein
04:36
ecancer

Safety & Efficacy of Asciminib for Heavily Pretreated Patients W…

Feat. M. Mauro
05:49
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in …

Feat. E. Stein
16:42
University of Miami's 2nd Biennial Miami Leukemia Symposium

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

Feat. E. Stein
06:19
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Feat. A. Mato
07:59
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Feat. A. Mato
05:08
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Feat. A. Mato
04:52
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Feat. A. Mato
08:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Feat. A. Mato
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…

Feat. M. Mauro
15:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

Feat. M. Mauro
27:00
Indy Hematology Review

Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…

Feat. M. Tallman
07:46
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients wi…

Feat. M. Mauro
17:58
Memorial Sloan Kettering Cancer Center

Front-line Strategies in Ph-negative ALL

Feat. M. Geyer
13:41
Memorial Sloan Kettering Cancer Center

Updates and Challenges in the Management of Chronic Myeloid Leukemia…

Feat. M. Mauro
17:13
Memorial Sloan Kettering Cancer Center

Multi-drug Resistant and Intolerant CML: What to Do?

Feat. M. Mauro
08:42
Memorial Sloan Kettering Cancer Center

IDH Inhibitors in AML

Feat. E. Stein